Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 2/20 | 0.41 |
| ▸ | SUMO2 | P61956 | 2/20 | 0.36 |
| ▸ | SUMO1 | P63165 | 2/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.36 |
| ▸ | SENP2 | Q9HC62 | 2/20 | 0.36 |
| ▸ | SENP3 | Q9H4L4 | 1/20 | 0.36 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ATIC | P31939 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28288401 | 0.98 | MYC (0.42) | MYCTTRSUMO2SUMO1SENP7 | |
| SCHEMBL7106886 | 0.83 | GAA (0.38) | ALDH1A1RXFP1L3MBTL1MCOLN3GAA | |
| SCHEMBL28650941 | 0.81 | HSD11B1 (0.40) | ALDH1A1RXFP1L3MBTL1MCOLN3KMT2A | |
| SCHEMBL29673477 | 0.81 | ALDH1A1 (0.37) | ALDH1A1RXFP1L3MBTL1MCOLN3KMT2A | |
| SCHEMBL1833873 | 0.81 | ALDH1A1 (0.37) | ALDH1A1RXFP1L3MBTL1MCOLN3KMT2A | |
| SCHEMBL4617196 | 0.81 | MEN1 (0.38) | MYCTTRSUMO2SUMO1SENP7 | |
| SCHEMBL20485803 | 0.79 | PTGES2 (0.44) | ALDH1A1KMT2AMEN1CDK2LMNA | |
| SCHEMBL31506947 | 0.78 | MYC (0.46) | MYCTTRSUMO2SUMO1SENP7 | |
| SCHEMBL153279 | 0.78 | MYC (0.46) | MYCTTRSUMO2SUMO1SENP7 | |
| SCHEMBL3780 | 0.78 | MYC (0.46) | MYCTTRSUMO2SUMO1SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365168-B1 | LIGHTWEIGHT FLAME RETARDANT THERMOPLASTIC STRUCTURES | SCHNELLER LLC (US) | 2021-06-30 | — | — | EP | claimed |
| EP-3365168-A1 | LIGHTWEIGHT FLAME RETARDANT THERMOPLASTIC STRUCTURES | Schneller, LLC (US) | 2018-08-29 | — | — | EP | claimed |
| WO-2017070276-A1 | LIGHTWEIGHT FLAME RETARDANT THERMOPLASTIC STRUCTURES | SCHNELLER LLC (US) | 2017-04-27 | — | — | WO | claimed |
| US-20170113445-A1 | LIGHTWEIGHT FLAME RETARDANT THERMOPLASTIC STRUCTURES | SCHNELLER LLC | 2017-04-27 | — | — | US | claimed |
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3707126-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20240425477-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2024-12-26 | — | — | US | disclosed |
| US-12071424-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2024-08-27 | — | — | US | disclosed |
| US-11898123-B2 | Cleaning compositions | FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) | 2024-02-13 | — | — | US | disclosed |
| CN-111566089-B | IRE1 small molecule inhibitors | 康奈尔大学 | 2023-11-17 | — | — | CN | disclosed |
| US-20230271935-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2023-08-31 | — | — | US | disclosed |
| US-20230271935-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2023-08-31 | — | — | US | disclosed |
| US-20120231632-A1 | Novel Etching Composition | FUJIFILM CORPORATION (JP) | 2012-09-13 | — | — | US | disclosed |
| WO-2009134637-A1 | PIPERAZINE-BASED CCR5 ANTAGONIST TABLET DOSAGE FORM | SCHERING CORPORATION (US) | 2009-11-05 | — | — | WO | disclosed |
| EP-0434739-B1 | PROCESS FOR THE PREPARATION OF 4-SULFO-2-CHLOROBENZOIC ACID | SOLVAY INTEROX LTD (GB) | 1995-03-29 | — | — | EP | disclosed |
| EP-0556421-A1 | Curable resin compositions | THE DOW CHEMICAL COMPANY (US) | 1993-08-25 | — | — | EP | disclosed |
| EP-0556429-A1 | Epoxy resin compositions | THE DOW CHEMICAL COMPANY (US) | 1993-08-25 | — | — | EP | disclosed |
| US-5139628-A | Selectively brominating 2-chloro-4-toluenesulfonic acid in anhydrous solvent with bromine dissociated by radiation, extracting into aqueous phase, hydrolyzing, oxidizing with percarboxylic acid or bromine | INTEROX CHEMICALS LIMITED (GB) | 1992-08-18 | — | — | US | disclosed |
| EP-0434739-A1 | PROCESS FOR THE PREPARATION OF 4-SULFO-2-CHLOROBENZOIC ACID. | INTEROX CHEMICALS LTD (GB) | 1991-07-03 | — | — | EP | disclosed |
| WO-1990002731-A1 | PROCESS FOR THE PREPARATION OF 4-SULFO-2-CHLOROBENZOIC ACID | INTEROX CHEMICALS LIMITED (GB) | 1990-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271935-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | MYC 1188/4885TTR 4273/4885SUMO2 1391/4885 |
| US-20240425477-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | MYC 1188/4885TTR 4273/4885SUMO2 1391/4885 |
| US-12071424-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | MYC 1188/4885TTR 4273/4885SUMO2 1391/4885 |
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | XBP1, DDIT3, HSP90B1 | MYC 2561/4885TTR 3861/4885SUMO2 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.